India's National Pharmaceutical Pricing Authority (NPPA) has proposed to cap the price of the diabetes combination therapy vildagliptin plus metformin at between INR 22.70 and INR 23.40 per tablet, reported Business Line.
According to the news source, the ceiling price is about four times higher than the price announced by domestic generic manufacturers, when the patent on the Novartis brand for the drug expired on December 9.
"Pre-December 9, four to five brands were present in the market which had priced the drug at close to INR 20 per tablet and the NPPA may have taken those prices under consideration," commented said Hari Natarajan of Pronto Consult.
"But from December 10 onwards, a flood of brands entered the market, which has lead to slashing of the prices. The NPPA fixes it's price based on market forces and it will have to revise it's proposal," Natarajan added.
To read more NewsPoints articles, click here.